Transaction #9356 · Form 4 · 0001193125-25-286226
Seres Therapeutics, Inc. · Exercise / conversion · Common Stock
Seres Therapeutics, Inc. · Transacted November 15, 2025 · Filed November 18, 2025
What does this filing report?
An SEC Form 4 filing for Seres Therapeutics, Inc. records an exercise / conversion involving Common Stock on November 15, 2025. The reported quantity was 98. The filing date is November 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Seres Therapeutics, Inc.
- Company CIK
- 0001609809
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 98
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 8,784
- Ownership description
- Not reported
- SEC acceptance time
- Nov 18, 2025, 4:30 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Henn Matthew R ↗
See Remarks
CIK 0001767321
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- F2
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- F3
- The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date.
- F4
- The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- F5
- The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Remarks
Chief Scientific Officer and EVP
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.